

Masaomi Nangaku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1149586/publications.pdf>

Version: 2024-02-01

402
papers

20,981
citations

7069

78
h-index

14156

128
g-index

470
all docs

470
docs citations

470
times ranked

19951
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 45-54.	0.4	3
2	Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. , 2022, 32, 432-440.		2
3	Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system. <i>Journal of Bone and Mineral Metabolism</i> , 2022, 40, 101-108.	1.3	13
4	Two long-term phase 3 studies of enarodustat (<sc>JTZ</sc>â€”951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: <sc>SYMPHONY NDâ€”Long</sc> and <sc>HDâ€”Long</sc> studies. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 345-356.	0.4	13
5	TRPM2 plays a minor role in acute kidney injury and kidney fibrosis. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0005492021.	0.9	6
6	Effect of Digital Health Among People With Type 2 Diabetes Mellitus During the COVID-19 Pandemic in Japan. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 256-258.	1.3	0
7	An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 19-28.	0.9	7
8	Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease. <i>Kidney International</i> , 2022, 101, 510-526.	2.6	36
9	Association Between Diabetes and Major Bleeding Complications of Renal Biopsy. <i>Kidney International Reports</i> , 2022, 7, 232-240.	0.4	7
10	Healthcare resource utilization in patients treated with empagliflozin in East Asia. <i>Journal of Diabetes Investigation</i> , 2022, 13, 810-821.	1.1	6
11	SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?. <i>Kidney International</i> , 2022, 101, 20-22.	2.6	1
12	Postoperative outcomes of cancer surgery in patients with and without kidney failure with dialysis therapy: a matched-pair cohort study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1137-1143.	1.4	3
13	Risk for Proteinuria in Newly Defined Hypertensive People Based on the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. <i>American Journal of Cardiology</i> , 2022, 168, 83-89.	0.7	2
14	Oxidized alkyl phospholipids stimulate sodium transport in proximal tubules via a nongenomic PPARÎ³-dependent pathway. <i>Journal of Biological Chemistry</i> , 2022, 298, 101681.	1.6	0
15	Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHERE, a Long-Term, Large-Scale Post-Marketing Surveillance. <i>Advances in Therapy</i> , 2022, 39, 674-691.	1.3	8
16	Change in Cardiovascular Health Metrics and Risk for Proteinuria Development: Analysis of a Nationwide Population-Based Database. <i>American Journal of Nephrology</i> , 2022, 53, 240-248.	1.4	8
17	Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CSâ€”150) and sodium-glucose cotransporterâ€”2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phaseâ€”III studies. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1190-1202.	1.1	9
18	Thyroid hormone increases oxygen metabolism causing intrarenal tissue hypoxia; a pathway to kidney disease. <i>PLoS ONE</i> , 2022, 17, e0264524.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. <i>American Journal of Nephrology</i> , 2022, 53, 307-315.	1.4	6
20	Effect of Information and Communication Technology-Based Self-management System DialBeticsLite on Treating Abdominal Obesity in the Specific Health Guidance in Japan: Randomized Controlled Trial. <i>JMIR Formative Research</i> , 2022, 6, e33852.	0.7	9
21	Exploring molecular targets in diabetic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2022, 41, S33-S45.	0.9	13
22	Anti-aging mechanism of calorie restriction in humans. <i>Kidney International</i> , 2022, 102, 223-225.	2.6	1
23	Neutrophil Protein Kinase R Mediates Endothelial Adhesion and Migration by the Promotion of Neutrophil Actin Polymerization. <i>Journal of Immunology</i> , 2022, 208, 2173-2183.	0.4	2
24	Safety of daproductat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2022, , .	0.4	3
25	Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors. <i>Biochemical and Biophysical Research Communications</i> , 2022, 605, 16-23.	1.0	1
26	Antibody recognition of complement Factor H reveals a flexible loop involved in Atypical Hemolytic Uremic Syndrome pathogenesis. <i>Journal of Biological Chemistry</i> , 2022, , 101962.	1.6	2
27	A Machine Learning-Based Predictive Model to Identify Patients Who Failed to Attend a Follow-up Visit for Diabetes Care After Recommendations From a National Screening Program. <i>Diabetes Care</i> , 2022, 45, 1346-1354.	4.3	2
28	An Investigation into Possible Sex Differences in Association of Hemoglobin with Survival Among Hemodialysis Patients in the J-DOPPS Cohort. <i>Nephrology</i> , 2022, , .	0.7	0
29	Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e060390.	0.8	20
30	Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient. <i>American Journal of Nephrology</i> , 2022, 53, 333-342.	1.4	9
31	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. <i>Diabetes Care</i> , 2022, 45, 1445-1452.	4.3	18
32	MO316: Eculizumab for Adult Patients With Atypical Haemolytic-Uremic Syndrome: Full Dataset Analysis of Post-Marketing Surveillance in Japan. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
33	Analysis of inflammatory cytokines and estimated glomerular filtration rate decline in Japanese patients with diabetic kidney disease: a pilot study. <i>Biomarkers in Medicine</i> , 2022, , .	0.6	0
34	Dapagliflozin for the treatment of chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 275-291.	1.2	7
35	Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1244-1252.	0.4	28
36	Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 642-653.	0.4	20

#	ARTICLE	IF	CITATIONS
37	Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested caseâ€“control study. <i>Rheumatology</i> , 2021, 60, 1717-1723.	0.9	4
38	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2021, 99, 2-4.	2.6	1
39	Recommendations by the Asian Pacific society of nephrology (<scp>APSN</scp>) on the appropriate use of <scp>HIFâ€“PH</scp> inhibitors. <i>Nephrology</i> , 2021, 26, 105-118.	0.7	60
40	Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 110-119.	0.7	4
41	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. <i>Kidney International</i> , 2021, 99, 256-266.	2.6	46
42	The Future of Nephrology and Public Health. <i>Contributions To Nephrology</i> , 2021, 199, 1-12.	1.1	3
43	Treatment of Diabetic Kidney Disease: Current and Future. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 11-26.	1.8	98
44	Aging-Related Kidney Diseases. <i>Contributions To Nephrology</i> , 2021, 199, 266-273.	1.1	8
45	Association between nutritional guidance or ophthalmological examination and discontinuation of physician visits in patients with newly diagnosed diabetes: A retrospective cohort study using a nationwide database. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1619-1631.	1.1	6
46	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 155-163.	0.9	9
47	Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. <i>American Journal of Nephrology</i> , 2021, 52, 26-35.	1.4	37
48	Update on diagnosis, pathophysiology, and management of diabetic kidney disease. <i>Nephrology</i> , 2021, 26, 491-500.	0.7	63
49	Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1731-1741.	0.4	36
50	Activation of Sympathetic Signaling in Macrophages Blocks Systemic Inflammation and Protects against Renal Ischemia-Reperfusion Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1599-1615.	3.0	17
51	Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1779-1790.	3.0	34
52	Incidence of Complications in 25 Adult Patients With X-linked Hypophosphatemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3682-e3692.	1.8	21
53	Nationwide survey of the coronavirus disease 2019 prevention and treatment systems for kidney disease patients: a study of Japanese Society of Nephrology-certified educational facilities. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 996-1002.	0.7	4
54	Infection prevention measures for patients undergoing hemodialysis during the COVID-19 pandemic in Japan: a nationwide questionnaire survey. <i>Renal Replacement Therapy</i> , 2021, 7, 27.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. <i>International Heart Journal</i> , 2021, 62, 592-600.	0.5	7
56	MO330ACTIVATION OF β_2 ADRENERGIC RECEPTOR SIGNALING IN MACROPHAGES BLOCKS SYSTEMIC INFLAMMATION AND PROTECTS AGAINST RENAL ISCHEMIA/REPERFUSION INJURY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
57	Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 979-987.	0.4	10
58	Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. <i>Scientific Reports</i> , 2021, 11, 11617.	1.6	9
59	Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1070-1078.	0.7	19
60	Does a preclinical randomized controlled trial, pRCT, resolve the gap between animal studies and human trials?. <i>Kidney International</i> , 2021, 99, 1262-1264.	2.6	2
61	Factors associated with long-term care certification in older adults: a cross-sectional study based on a nationally representative survey in Japan. <i>BMC Geriatrics</i> , 2021, 21, 374.	1.1	7
62	A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. <i>Kidney International Reports</i> , 2021, 6, 1840-1849.	0.4	22
63	Preexisting heart failure with reduced ejection fraction attenuates renal fibrosis after ischemia reperfusion via sympathetic activation. <i>Scientific Reports</i> , 2021, 11, 15091.	1.6	4
64	A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 494-502.	1.2	21
65	Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3477-3486.	1.8	4
66	Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e31061.	0.5	6
67	A novel method for successful induction of interdigitating process formation in conditionally immortalized podocytes from mice, rats, and humans. <i>Biochemical and Biophysical Research Communications</i> , 2021, 570, 47-52.	1.0	2
68	Decreased IFT88 expression with primary cilia shortening causes mitochondrial dysfunction in cisplatin-induced tubular injury. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, F278-F292.	1.3	11
69	Potassium Concentration in Initial Fluid Therapy and In-Hospital Mortality of Patients with Diabetic Ketoacidosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2162-e2175.	1.8	4
70	Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-5.	0.6	1
71	A distinctive distribution of hypoxia-inducible factor-1 α in cultured renal tubular cells with hypoperfusion simulated by coverslip placement. <i>Physiological Reports</i> , 2021, 9, e14689.	0.7	1
72	4. Oxygen Sensing Mechanisms and Nobel Prize. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 77a-80a.	0.0	0

#	ARTICLE	IF	CITATIONS
73	V. AKI to CKD - Transitional Mechanisms from AKI to CKD. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 928-934.	0.0	0
74	Insulin promotes sodium transport but suppresses gluconeogenesis via distinct cellular pathways in human and rat renal proximal tubules. Kidney International, 2020, 97, 316-326.	2.6	19
75	Munc18-1-interacting protein 3 mitigates renal fibrosis through protection of tubular epithelial cells from apoptosis. Nephrology Dialysis Transplantation, 2020, 35, 576-586.	0.4	6
76	Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase. Journal of Atherosclerosis and Thrombosis, 2020, 27, 353-362.	0.9	11
77	Modulating the immune system to delay the clinical onset of type 1 diabetes. Kidney International, 2020, 97, 248-250.	2.6	1
78	JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. American Journal of Physiology - Renal Physiology, 2020, 318, F14-F24.	1.3	17
79	The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney International, 2020, 97, 934-950.	2.6	73
80	Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease. American Journal of Physiology - Renal Physiology, 2020, 318, F388-F401.	1.3	34
81	Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Current Opinion in Nephrology and Hypertension, 2020, 29, 128-135.	1.0	33
82	Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. Kidney International, 2020, 97, 687-701.	2.6	50
83	The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. British Journal of Haematology, 2020, 189, 182-186.	1.2	6
84	More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD. Kidney International, 2020, 98, 1387-1389.	2.6	6
85	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	2.6	65
86	Hierarchical Clustering Analysis for Predicting 1-Year Mortality After Starting Hemodialysis. Kidney International Reports, 2020, 5, 1188-1195.	0.4	16
87	Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN). Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1715-1727.	2.2	123
88	Sixty (plus one) breakthrough discoveries in nephrology. Kidney International, 2020, 98, 1362-1366.	2.6	3
89	The Nobel Prize in chemistry in 2020: genome editing tools and their immeasurable applications for humankind. Kidney International, 2020, 98, 1367-1369.	2.6	2
90	Lysine demethylase 7a regulates murine anterior-posterior development by modulating the transcription of Hox gene cluster. Communications Biology, 2020, 3, 725.	2.0	7

#	ARTICLE	IF	CITATIONS
91	Association Between IV Thiamine and Mortality in Patients With Septic Shock: A Nationwide Observational Study. <i>Critical Care Medicine</i> , 2020, 48, 1135-1139.	0.4	21
92	Intracellular calcium response of primary cilia of tubular cells to modulated shear stress under oxidative stress. <i>Biomicrofluidics</i> , 2020, 14, 044102.	1.2	5
93	Hypoxia-Inducible Factor and Oxygen Biology in the Kidney. <i>Kidney360</i> , 2020, 1, 1021-1031.	0.9	20
94	Different Biomarker Kinetics in Critically Ill Patients with High Lactate Levels. <i>Diagnostics</i> , 2020, 10, 454.	1.3	3
95	Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1155-1165.	2.2	80
96	Inverse Correlation Between Incidence and Mortality of Acute Kidney Injury in Critically Ill Patients: A Systematic Review. <i>Shock</i> , 2020, 54, 280-284.	1.0	5
97	Metforminâ€”to use or not to use . . . is that the question?. <i>Kidney International</i> , 2020, 98, 1105-1107.	2.6	1
98	Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis. <i>Scientific Reports</i> , 2020, 10, 15663.	1.6	7
99	A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity. <i>Scientific Reports</i> , 2020, 10, 17565.	1.6	2
100	Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105341.	0.7	4
101	Urinary Neutrophil Gelatinase-Associated Lipocalin in Critically Ill Patients With Coronavirus Disease 2019. , 2020, 2, e0181.		12
102	SchlÃ¼ndorff and Lee revealed crosstalk between glomerular cells and a role of BAMBI in diabetic kidney disease. <i>Kidney International</i> , 2020, 98, 539-541.	2.6	1
103	New insights into tubular cell recovery after ischemic acute kidney injury. <i>Kidney International</i> , 2020, 97, 845-846.	2.6	1
104	Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 560-577.	3.0	72
105	The cellular model of albumin endocytosis uncovers link between membrane and nuclear proteins. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	5
106	Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 414-422.	1.0	19
107	Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study). <i>Kidney International Reports</i> , 2020, 5, 879-890.	0.4	82
108	Founding papers of current nephrology: from acute kidney injury to diabetic kidney disease. <i>Kidney International</i> , 2020, 98, 6-9.	2.6	1

#	ARTICLE	IF	CITATIONS
109	<scp>COVID</scp>â€19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic Apheresis and Dialysis, 2020, 24, 361-365.	0.4	53
110	Vagus nerve stimulation even after injury ameliorates cisplatin-induced nephropathy via reducing macrophage infiltration. Scientific Reports, 2020, 10, 9472.	1.6	12
111	SOO49HYPOXIA INDUCIBLE FACTOR-PROLYL HYDROXYLASE (HIF-PH) INHIBITION COUNTERACTS THE RENAL ENERGY METABOLISM ALTERATIONS IN THE EARLY STAGES OF DIABETIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
112	Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure. PLoS ONE, 2020, 15, e0229397.	1.1	5
113	Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells. EMBO Journal, 2020, 39, e103949.	3.5	37
114	The role of hypoxia in the pathogenesis of lupus nephritis. Kidney International, 2020, 98, 821-823.	2.6	2
115	Global case studies for chronic kidney disease/end-stage kidney disease care. Kidney International Supplements, 2020, 10, e24-e48.	4.6	53
116	Visualizing fibrosisâ€”hope for ideal markers beyond imaging. Kidney International, 2020, 97, 437-438.	2.6	2
117	Recombinant thrombomodulin prevents acute lung injury induced by renal ischemia-reperfusion injury. Scientific Reports, 2020, 10, 289.	1.6	24
118	Outcomes of lactulose plus branchedâ€”chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. Hepatology Research, 2020, 50, 693-703.	1.8	5
119	Correlation between the Incidence and Attributable Mortality Fraction of Acute Kidney Injury: A Systematic Review. Blood Purification, 2020, 49, 386-393.	0.9	2
120	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e000902.	1.2	31
121	Regional variance in the use of urine dipstick test for outpatients in Japan. Nephrology, 2020, 25, 676-682.	0.7	4
122	Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 608-615.	2.2	10
123	Using mHealth to Provide Mobile App Users With Visualization of Health Checkup Data and Educational Videos on Lifestyle-Related Diseases: Methodological Framework for Content Development. JMIR MHealth and UHealth, 2020, 8, e20982.	1.8	8
124	Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 1, 740-745.	0.9	4
125	Willingness of Patients Prescribed Medications for Lifestyle-Related Diseases to Use Personal Health Records: Questionnaire Study. Journal of Medical Internet Research, 2020, 22, e13866.	2.1	4
126	Identification of ENPP1 Haploinsufficiency in Patients With Diffuse Idiopathic Skeletal Hyperostosis and Early-Onset Osteoporosis. Journal of Bone and Mineral Research, 2020, 37, 1125-1135.	3.1	18

#	ARTICLE	IF	CITATIONS
127	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 112-121.	0.7	31
128	Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 65-75.	0.7	15
129	JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, stabilizes HIF-1 α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. <i>European Journal of Pharmacology</i> , 2019, 859, 172532.	1.7	32
130	Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1161-1172.	2.2	85
131	Novel CFHR2-CFHR1 Hybrid in C3 Glomerulopathy Identified by Genomic Structural Variation Analysis. <i>Kidney International Reports</i> , 2019, 4, 1759-1762.	0.4	3
132	Podocyte lipotoxicity in diabetic kidney disease. <i>Kidney International</i> , 2019, 96, 809-812.	2.6	16
133	Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury. <i>Cell Reports</i> , 2019, 29, 1261-1273.e6.	2.9	302
134	Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?. <i>Kidney International</i> , 2019, 96, 823-825.	2.6	5
135	Association between intravenous contrast media exposure and non-recovery from dialysis-requiring septic acute kidney injury: a nationwide observational study. <i>Intensive Care Medicine</i> , 2019, 45, 1570-1579.	3.9	14
136	New measures against chronic kidney diseases in Japan since 2018. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 1263-1271.	0.7	17
137	Non-canonical cholinergic anti-inflammatory pathway-mediated activation of peritoneal macrophages induces Hes1 and blocks ischemia/reperfusion injury in the kidney. <i>Kidney International</i> , 2019, 95, 563-576.	2.6	37
138	A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. <i>American Journal of Nephrology</i> , 2019, 49, 165-174.	1.4	62
139	Light of dawn in Melbourne: SONAR and CREDESCENCE. <i>Kidney International</i> , 2019, 96, 2-4.	2.6	1
140	Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?. <i>Kidney International</i> , 2019, 96, 8-10.	2.6	9
141	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. <i>Nephron</i> , 2019, 143, 77-85.	0.9	36
142	Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. <i>Endocrine Journal</i> , 2019, 66, 683-689.	0.7	6
143	Temporal change in characteristics and outcomes of acute kidney injury on renal replacement therapy in intensive care units: analysis of a nationwide administrative database in Japan, 2007-2016. <i>Critical Care</i> , 2019, 23, 172.	2.5	23
144	In vivo rendezvous of small nucleic acid drugs with charge-matched block cationomers to target cancers. <i>Nature Communications</i> , 2019, 10, 1894.	5.8	53

#	ARTICLE	IF	CITATIONS
145	Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury. <i>Kidney International</i> , 2019, 96, 129-138.	2.6	34
146	Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. <i>Contributions To Nephrology</i> , 2019, 198, 112-123.	1.1	22
147	Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome. <i>Endocrine Journal</i> , 2019, 66, 547-554.	0.7	1
148	Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. <i>Laboratory Investigation</i> , 2019, 99, 1217-1232.	1.7	33
149	Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease. <i>Annals of Hematology</i> , 2019, 98, 1995-1997.	0.8	1
150	Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. <i>Annals of Translational Medicine</i> , 2019, 7, S334-S334.	0.7	4
151	Kidney International celebrates the 60th anniversary of the International Society of Nephrology. <i>Kidney International</i> , 2019, 96, 1248-1249.	2.6	2
152	Extraperitoneal Placement of a Peritoneal Dialysis Catheter. <i>Internal Medicine</i> , 2019, 58, 147-148.	0.3	0
153	Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 231-243.	0.7	9
154	Pathogenesis of Atypical Hemolytic Uremic Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 99-110.	0.9	53
155	Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME [®] trial. <i>Journal of Diabetes Investigation</i> , 2019, 10, 760-770.	1.1	61
156	Tipping the Balance from Angiogenesis to Fibrosis in Chronic Kidney Disease. <i>Molecular and Translational Medicine</i> , 2019, , 419-449.	0.4	0
157	Regulatory roles of hypoxia-inducible, noncoding RNAs on mitochondrial dynamics during AKI. <i>Kidney International</i> , 2019, 95, 252-253.	2.6	2
158	ATF6 [±] downregulation of PPAR [±] promotes lipotoxicity-induced tubulointerstitial fibrosis. <i>Kidney International</i> , 2019, 95, 577-589.	2.6	86
159	Kinetic estimated glomerular filtration rate as a predictor of successful continuous renal replacement therapy discontinuation. <i>Nephrology</i> , 2019, 24, 287-293.	0.7	20
160	Usage Patterns of GlucoNote, a Self-Management Smartphone App, Based on ResearchKit for Patients With Type 2 Diabetes and Prediabetes. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13204.	1.8	35
161	The role of oxidative stress and hypoxia in renal disease. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 414-426.	0.9	97
162	Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. , 2019, 1, e0008.		2

#	ARTICLE	IF	CITATIONS
163	The Sendai declaration for the eradication of kidney disease. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1-2.	0.7	3
164	Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes. <i>Scientific Reports</i> , 2018, 8, 3779.	1.6	17
165	Intravital phosphorescence lifetime imaging of the renal cortex accurately measures renal hypoxia. <i>Kidney International</i> , 2018, 93, 1483-1489.	2.6	31
166	Modest Impact of Serial Measurements of Acute Kidney Injury Biomarkers in an Adult Intensive Care Unit. <i>Nephron</i> , 2018, 139, 243-253.	0.9	4
167	H ⁺ -ATPase blockade reduced renal gluconeogenesis and plasma glucose in a diabetic rat model. <i>Medical Molecular Morphology</i> , 2018, 51, 89-95.	0.4	6
168	Controversies of the classification of TMA and the terminology of aHUS. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 979-980.	0.7	10
169	Glomeruloid hemangioma associated with TAFRO syndrome. <i>Human Pathology</i> , 2018, 82, 172-176.	1.1	8
170	Functional splicing analysis in an infantile case of atypical hemolytic uremic syndrome caused by digenic mutations in C3 and MCP genes. <i>Journal of Human Genetics</i> , 2018, 63, 755-759.	1.1	7
171	Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1088-1099.	0.7	35
172	Urinary N-acetylgalactosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immunosuppression at diagnosis in idiopathic membranous nephropathy. <i>Nephrology</i> , 2018, 23, 175-182.	0.7	4
173	Rationale and design of observational clinical Research In chronic kidney disease patients with renal anemia: renal prognosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetin alfa (BRIGHTEN Trial). <i>Clinical and Experimental Nephrology</i> , 2018, 22, 78-84.	0.7	6
174	Pulmonary nonsegmental micronodules in a patient undergoing hemodialysis. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 201-202.	0.7	0
175	Diabetic Kidney Disease. , 2018, , 1-17.		2
176	Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 318-327.	0.7	33
177	Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population. <i>Nephrology</i> , 2018, 23, 821-829.	0.7	16
178	Damage-associated molecular patterns in intensive care unit patients with acute liver injuries. <i>Medicine (United States)</i> , 2018, 97, e12780.	0.4	4
179	Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway. <i>Kidney International</i> , 2018, 94, 1038-1039.	2.6	3
180	The Lasker Prize award 2018: histones – the story. <i>Kidney International</i> , 2018, 94, 1032-1034.	2.6	2

#	ARTICLE	IF	CITATIONS
181	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 925-933.	5.5	30
182	Guidelines for clinical evaluation of chronic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1446-1475.	0.7	23
183	Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan. <i>Haematologica</i> , 2018, 103, 1815-1824.	1.7	22
184	Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. <i>Kidney International</i> , 2018, 94, 912-925.	2.6	123
185	Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 331-338.	1.0	43
186	Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response. <i>Kidney International</i> , 2018, 94, 536-550.	2.6	30
187	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. <i>Journal of Diabetes Investigation</i> , 2017, 8, 261-271.	1.1	37
188	Oxygen imaging of living cells and tissues using luminescent molecular probes. <i>Journal of Photochemistry and Photobiology C: Photochemistry Reviews</i> , 2017, 30, 71-95.	5.6	98
189	Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. <i>American Journal of Nephrology</i> , 2017, 45, 127-135.	1.4	85
190	Applications of the CRISPR-Cas9 system in kidney research. <i>Kidney International</i> , 2017, 92, 324-335.	2.6	15
191	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet</i> , 2017, 390, 1888-1917.	6.3	662
192	ACE2 as therapy for glomerular disease: the devil is in the detail. <i>Kidney International</i> , 2017, 91, 1269-1271.	2.6	13
193	Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. <i>Physiological Reports</i> , 2017, 5, e13203.	0.7	31
194	Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. <i>Diabetes</i> , 2017, 66, 2339-2350.	0.3	61
195	Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. <i>Kidney International</i> , 2017, 92, 154-164.	2.6	37
196	Previous dropout from diabetic care as a predictor of patients' willingness to use mobile applications for self-management: A cross-sectional study. <i>Journal of Diabetes Investigation</i> , 2017, 8, 542-549.	1.1	16
197	Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	98
198	Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. <i>Kidney International Supplements</i> , 2017, 7, 122-129.	4.6	106

#	ARTICLE	IF	CITATIONS
199	D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation. <i>Scientific Reports</i> , 2017, 7, 11168.	1.6	38
200	Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner. <i>Scientific Reports</i> , 2017, 7, 6516.	1.6	31
201	Epigenetic Changes in the Acute Kidney Injury-to-Chronic Kidney Disease Transition. <i>Nephron</i> , 2017, 137, 256-259.	0.9	40
202	Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. <i>Kidney International</i> , 2017, 92, 306-312.	2.6	98
203	2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. <i>Renal Replacement Therapy</i> , 2017, 3, .	0.3	137
204	Heterogeneity of clinical indices among the older dialysis population—a study on Japanese dialysis population. <i>Renal Replacement Therapy</i> , 2017, 3, .	0.3	7
205	Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 961-970.	0.7	13
206	The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease. <i>Kidney International Reports</i> , 2017, 2, 60-65.	0.4	4
207	Renal Hypoxia in CKD; Pathophysiology and Detecting Methods. <i>Frontiers in Physiology</i> , 2017, 8, 99.	1.3	73
208	Targeting gene expression to specific cells of kidney tubules in vivo, using adenoviral promoter fragments. <i>PLoS ONE</i> , 2017, 12, e0168638.	1.1	13
209	Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study. <i>JMIR Research Protocols</i> , 2017, 6, e63.	0.5	33
210	Erythropoietin concentration in acute kidney injury is associated with insulin-like growth factor-binding protein-1. <i>Nephrology</i> , 2016, 21, 693-699.	0.7	12
211	Quantitating intracellular oxygen tension in vivo by phosphorescence lifetime measurement. <i>Scientific Reports</i> , 2016, 5, 17838.	1.6	43
212	DialBetics. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 804-805.	1.3	8
213	Hypoxia-Inducible Factor-1 α Activates the Transforming Growth Factor- β /SMAD3 Pathway in Kidney Tubular Epithelial Cells. <i>American Journal of Nephrology</i> , 2016, 44, 276-285.	1.4	54
214	Lactoferrin Suppresses Neutrophil Extracellular Traps Release in Inflammation. <i>EBioMedicine</i> , 2016, 10, 204-215.	2.7	131
215	Hypoxia and hypoxia-inducible factors in chronic kidney disease. <i>Renal Replacement Therapy</i> , 2016, 2, .	0.3	24
216	New insights into molecular mechanisms of epigenetic regulation in kidney disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 1159-1167.	0.9	17

#	ARTICLE	IF	CITATIONS
217	Impact of clinical context on acute kidney injury biomarker performances: differences between neutrophil gelatinase-associated lipocalin and L-type fatty acid-binding protein. <i>Scientific Reports</i> , 2016, 6, 33077.	1.6	23
218	Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist. <i>Journal of Biological Chemistry</i> , 2016, 291, 22460-22471.	1.6	16
219	Clinical guides for atypical hemolytic uremic syndrome in Japan. <i>Clinical and Experimental Nephrology</i> , 2016, 20, 536-543.	0.7	41
220	No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome. <i>International Journal of Hematology</i> , 2016, 104, 223-227.	0.7	7
221	Correction of Metabolic Alkalosis and Elevated Calcium Levels by Sodium Chloride in a Hemodialysis Patient With Inadequate Chloride Intake. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 86-87.	0.4	1
222	Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. <i>Kidney International</i> , 2016, 89, 374-385.	2.6	63
223	The reduced expression of proximal tubular transporters in acquired Fanconi syndrome with light chain deposition. <i>Medical Molecular Morphology</i> , 2016, 49, 48-52.	0.4	3
224	Progression after AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 687-697.	3.0	351
225	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). <i>Clinical and Experimental Nephrology</i> , 2016, 20, 71-76.	0.7	7
226	Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins. <i>Nephrology</i> , 2015, 20, 101-104.	0.7	3
227	Arteriolar hyalinosis and arterial hypertension as possible surrogate markers of reduced interstitial blood flow and hypoxia in glomerulonephritis. <i>Nephrology</i> , 2015, 20, 11-17.	0.7	17
228	Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2015, 8, 103.	1.1	16
229	High (pH 6.5) Spontaneous and Persistent Urinary pH Is Protective of Renal Function at Baseline and during Disease Course in Idiopathic Membranous Nephropathy. <i>International Journal of Nephrology</i> , 2015, 2015, 1-7.	0.7	0
230	Recent advances in understanding of chronic kidney disease. <i>F1000Research</i> , 2015, 4, 1212.	0.8	27
231	A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 708-715.	1.4	61
232	How the Target Hemoglobin of Renal Anemia Should Be?. <i>Nephron</i> , 2015, 131, 202-209.	0.9	287
233	Hypoxia and Dysregulated Angiogenesis in Kidney Disease. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 80-89.	1.2	58
234	Role of Uremic Toxins in Erythropoiesis-Stimulating Agent Resistance in Chronic Kidney Disease and Dialysis Patients. , 2015, 25, 160-163.		34

#	ARTICLE	IF	CITATIONS
235	Regulation of Mitochondrial Dynamics by Dynamin-Related Protein-1 in Acute Cardiorenal Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2378-2387.	3.0	98
236	Epigenetic Changes Induced by Hypoxia-Inducible Factor: a Long Way Still To Go as a Target for Therapy?. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1478-1480.	3.0	8
237	Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein β . <i>Kidney International</i> , 2015, 88, 262-275.	2.6	64
238	Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 925-932.	0.7	6
239	Glypican-5 Increases Susceptibility to Nephrotic Damage in Diabetic Kidney. <i>American Journal of Pathology</i> , 2015, 185, 1889-1898.	1.9	18
240	Endothelin-converting enzyme is a plausible target gene for hypoxia-inducible factor. <i>Kidney International</i> , 2015, 87, 761-770.	2.6	20
241	Sirtuin1 Maintains Actin Cytoskeleton by Deacetylation of Cortactin in Injured Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1939-1959.	3.0	56
242	Activation of Hypoxia-Inducible Factors Prevents Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 328-338.	3.0	166
243	Adult stem-like cells in kidney. <i>World Journal of Stem Cells</i> , 2015, 7, 490.	1.3	14
244	Long-Term Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation by Era. <i>Clinical Transplants</i> , 2015, 31, 35-42.	0.2	0
245	Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study. <i>Critical Care</i> , 2014, 18, 716.	2.5	42
246	Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes. <i>Kidney International Supplements</i> , 2014, 4, 107-112.	4.6	67
247	The Authors Reply:. <i>Kidney International</i> , 2014, 86, 208-209.	2.6	0
248	The Authors Reply. <i>Kidney International</i> , 2014, 86, 210.	2.6	0
249	The high-mobility group protein B1 α €™Toll-like receptor 4 pathway contributes to the acute lung injury induced by bilateral nephrectomy. <i>Kidney International</i> , 2014, 86, 316-326.	2.6	58
250	Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F1171-F1178.	1.3	15
251	Repulsive guidance cue semaphorin 3A in urine predicts the progression of acute kidney injury in adult patients from a mixed intensive care unit. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 73-80.	0.4	19
252	ANO1: an additional key player in cyst growth. <i>Kidney International</i> , 2014, 85, 1007-1009.	2.6	9

#	ARTICLE	IF	CITATIONS
253	Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2316-2326.	0.4	29
254	A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. <i>Kidney International</i> , 2014, 85, 641-648.	2.6	76
255	<scp>G</scp>lyoxalase <scp>I</scp> reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation. <i>Aging Cell</i> , 2014, 13, 519-528.	3.0	56
256	Galacto-oligosaccharides attenuate renal injury with microbiota modification. <i>Physiological Reports</i> , 2014, 2, e12029.	0.7	46
257	Role of hypoxia in progressive chronic kidney disease and implications for therapy. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 161-168.	1.0	66
258	Revolution of nephrology research by deep sequencing: CHIP-seq and RNA-seq. <i>Kidney International</i> , 2014, 85, 31-38.	2.6	38
259	Proteostasis in endoplasmic reticulum—new mechanisms in kidney disease. <i>Nature Reviews Nephrology</i> , 2014, 10, 369-378.	4.1	170
260	Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 4-9.	0.7	24
261	The potential for renoprotection with incretin-based drugs. <i>Kidney International</i> , 2014, 86, 701-711.	2.6	103
262	Hypoxia as a key player in the AKI-to-CKD transition. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F1187-F1195.	1.3	202
263	Cross-enhancement of ANGPTL4 transcription by HIF1 alpha and PPAR beta/delta is the result of the conformational proximity of two response elements. <i>Genome Biology</i> , 2014, 15, R63.	13.9	58
264	Genome-wide analysis of murine renal distal convoluted tubular cells for the target genes of mineralocorticoid receptor. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 132-137.	1.0	33
265	Development of systemic lupus erythematosus in an elderly male hemodialysis patient with pleuritis. <i>CEN Case Reports</i> , 2013, 2, 46-48.	0.5	1
266	Regulation of hypoxia-inducible factor in kidney disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 148-157.	0.9	112
267	Sperm-Associated Antigen 4, a Novel Hypoxia-Inducible Factor 1 Target, Regulates Cytokinesis, and Its Expression Correlates with the Prognosis of Renal Cell Carcinoma. <i>American Journal of Pathology</i> , 2013, 182, 2191-2203.	1.9	27
268	Novel Therapeutic Strategy With Hypoxia-Inducible Factors via Reversible Epigenetic Regulation Mechanisms in Progressive Tubulointerstitial Fibrosis. <i>Seminars in Nephrology</i> , 2013, 33, 375-382.	0.6	40
269	Endoplasmic reticulum stress signal impairs erythropoietin production: a role for ATF4. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 304, C342-C353.	2.1	39
270	Angiogenesis and hypoxia in the kidney. <i>Nature Reviews Nephrology</i> , 2013, 9, 211-222.	4.1	118

#	ARTICLE	IF	CITATIONS
271	Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2013, 54, 238-246.	1.0	62
272	Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 965-976.	2.5	14
273	Oxidative and Endoplasmic Reticulum (ER) Stress in Tissue Fibrosis. <i>Current Pathobiology Reports</i> , 2013, 1, 283-289.	1.6	4
274	A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F1796-F1803.	1.3	24
275	Tissue protection by erythropoietin: new findings in a moving field. <i>Kidney International</i> , 2013, 84, 427-429.	2.6	17
276	Energy policy of the kidney: launch of AMPK as a novel therapeutic target. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F977-F978.	1.3	3
277	Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. <i>FASEB Journal</i> , 2013, 27, 4059-4075.	0.2	42
278	Hypoxia-inducible factor and signal transducer and activators of transcription 3: two central regulators meet to regulate kidney pathophysiology. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 251-252.	0.9	0
279	Kidney Hypoxia, Attributable to Increased Oxygen Consumption, Induces Nephropathy Independently of Hyperglycemia and Oxidative Stress. <i>Hypertension</i> , 2013, 62, 914-919.	1.3	137
280	Blocking Properdin, the Alternative Pathway, and Anaphylatoxin Receptors Ameliorates Renal Ischemia-Reperfusion Injury in Decay-Accelerating Factor and CD59 Double-Knockout Mice. <i>Journal of Immunology</i> , 2013, 190, 3552-3559.	0.4	67
281	Dynamic Change of Chromatin Conformation in Response to Hypoxia Enhances the Expression of GLUT3 (SLC2A3) by Cooperative Interaction of Hypoxia-Inducible Factor 1 and KDM3A. <i>Molecular and Cellular Biology</i> , 2012, 32, 3018-3032.	1.1	230
282	Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host. <i>Journal of Biological Chemistry</i> , 2012, 287, 34866-34882.	1.6	40
283	Image of Erdheim-Chester disease requiring hemodialysis. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 811-812.	0.7	4
284	Dysregulated Oxygen Metabolism of the Kidney by Uremic Toxins: Review. , 2012, 22, 77-80.		26
285	Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. <i>Experimental Cell Research</i> , 2012, 318, 1068-1073.	1.2	45
286	Downregulation of miR-205 Modulates Cell Susceptibility to Oxidative and Endoplasmic Reticulum Stresses in Renal Tubular Cells. <i>PLoS ONE</i> , 2012, 7, e41462.	1.1	99
287	Cytoglobin, a Novel Member of the Globin Family, Protects Kidney Fibroblasts against Oxidative Stress under Ischemic Conditions. <i>American Journal of Pathology</i> , 2011, 178, 128-139.	1.9	50
288	Glyoxalase I Retards Renal Senescence. <i>American Journal of Pathology</i> , 2011, 179, 2810-2821.	1.9	41

#	ARTICLE	IF	CITATIONS
289	Pathophysiological Response to Hypoxia " From the Molecular Mechanisms of Malady to Drug Discovery: Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes. <i>Journal of Pharmacological Sciences</i> , 2011, 115, 453-458.	1.1	33
290	Introduction: Hearing footsteps of the future. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2011, 38, 438-440.	0.9	1
291	Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. <i>Laboratory Investigation</i> , 2011, 91, 1564-1571.	1.7	132
292	Diary of a Japanese nephrologist during the present disaster. <i>Kidney International</i> , 2011, 79, 1037-1039.	2.6	12
293	Diary of a Japanese nephrologist during the present disaster: part II. <i>Kidney International</i> , 2011, 80, 3-5.	2.6	1
294	Novel Members of the Globin Family and Their Function Against Oxidative Stress. , 2011, , 105-117.		1
295	Increased mitochondrial uncoupling results in renal tissue hypoxia and proteinuria. <i>FASEB Journal</i> , 2011, 25, 664.4.	0.2	0
296	The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 43-50.	1.0	66
297	Chronic Interstitial Nephritis. , 2010, , 748-760.		1
298	Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F568-F576.	1.3	75
299	Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F380-F386.	1.3	68
300	Forewarned is forearmed: arm with HIF activation. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1385-1387.	0.4	4
301	Cytoglobin, a novel globin, plays an antifibrotic role in the kidney. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F1120-F1133.	1.3	42
302	The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. <i>Nature Reviews Nephrology</i> , 2010, 6, 667-678.	4.1	251
303	The Role of Glyoxalase System in Renal Hypoxia. <i>Advances in Experimental Medicine and Biology</i> , 2010, 662, 49-55.	0.8	16
304	Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. <i>Kidney International</i> , 2009, 75, 268-277.	2.6	49
305	Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2665-2672.	0.4	92
306	Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F912-F921.	1.3	81

#	ARTICLE	IF	CITATIONS
307	Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Prolyl-Hydroxylase Inhibitors to Activate Hypoxia-Inducible Factor (HIF) as a Novel Therapeutic Approach in CKD. <i>Journal of Pharmacological Sciences</i> , 2009, 109, 24-31.	1.1	37
308	Novel Therapeutic Approach Targeting The Hif-Hre System In The Kidney. <i>Advances in Experimental Medicine and Biology</i> , 2009, 645, 81-86.	0.8	7
309	Hypoxia and Hypoxia-Inducible Factor in Renal Disease. <i>Nephron Experimental Nephrology</i> , 2008, 110, e1-e7.	2.4	79
310	Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 305-310.	1.0	19
311	Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. <i>Clinica Chimica Acta</i> , 2008, 388, 51-58.	0.5	99
312	Hemoglobin Is Expressed by Mesangial Cells and Reduces Oxidant Stress. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1500-1508.	3.0	135
313	Chronic hypoxia aggravates renal injury via suppression of Cu/Zn-SOD: a proteomic analysis. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F62-F72.	1.3	37
314	Inhibition of Plasminogen Activator Inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 672-677.	1.1	116
315	Preconditioning with Endoplasmic Reticulum Stress Ameliorates Mesangioproliferative Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 915-922.	3.0	99
316	Activation of the Renin-Angiotensin System and Chronic Hypoxia of the Kidney. <i>Hypertension Research</i> , 2008, 31, 175-184.	1.5	82
317	The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. <i>Kidney International</i> , 2008, 74, 768-774.	2.6	12
318	Role of chronic hypoxia and hypoxia inducible factor in kidney disease. <i>Chinese Medical Journal</i> , 2008, 121, 257-64.	0.9	4
319	The Heat Is On: An Expanding Role for Hypoxia-Inducible Factors in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 13-15.	3.0	2
320	Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1166-1172.	0.4	123
321	Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. <i>Biochemical and Biophysical Research Communications</i> , 2007, 359, 928-934.	1.0	76
322	The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. <i>Pharmacological Reviews</i> , 2007, 59, 251-287.	7.1	1,082
323	Protective Role of Hypoxia-Inducible Factor-2 α against Ischemic Damage and Oxidative Stress in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1218-1226.	3.0	119
324	A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2548-2554.	1.1	112

#	ARTICLE	IF	CITATIONS
325	Hypoxia and the HIF system in kidney disease. <i>Journal of Molecular Medicine</i> , 2007, 85, 1325-1330.	1.7	212
326	Pathogenesis and prognosis of thrombotic microangiopathy. <i>Clinical and Experimental Nephrology</i> , 2007, 11, 107-114.	0.7	19
327	Angiotensin-Induced Hypoxia in the Kidney: Functional and Structural Changes of the Renal Circulation. <i>Advances in Experimental Medicine and Biology</i> , 2007, 618, 85-99.	0.8	13
328	Pathogenesis of Renal Anemia. <i>Seminars in Nephrology</i> , 2006, 26, 261-268.	0.6	159
329	Chronic Hypoxia and Tubulointerstitial Injury: A Final Common Pathway to End-Stage Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 17-25.	3.0	985
330	Hypoxia and Expression of Hypoxia-Inducible Factor in the Aging Kidney. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 795-805.	1.7	88
331	A Cry for polar shedding. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1773-1775.	0.4	1
332	Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 129-139.	1.5	32
333	Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action. <i>Current Hypertension Reviews</i> , 2006, 2, 325-331.	0.5	0
334	A Severe Diabetic Nephropathy Model With Early Development of Nodule-Like Lesions Induced by Megsin Overexpression in RAGE/iNOS Transgenic Mice. <i>Diabetes</i> , 2006, 55, 356-366.	0.3	83
335	High Glucose Blunts Vascular Endothelial Growth Factor Response to Hypoxia via the Oxidative Stress-Regulated Hypoxia-Inducible Factor/Hypoxia-Responsible Element Pathway. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1405-1413.	3.0	115
336	Clinical Outcome of Thrombotic Microangiopathy after Living-Donor Liver Transplantation Treated with Plasma Exchange Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 811-819.	2.2	19
337	Cellular and molecular biology of membranous nephropathy. <i>Journal of Nephrology</i> , 2006, 19, 699-705.	0.9	34
338	Synergistic Contributions of Carbonyl Stress and Megsin in Diabetic Nephropathy. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 605-608.	1.8	4
339	A biologic role of HIF-1 in the renal medulla. <i>Kidney International</i> , 2005, 67, 1428-1439.	2.6	59
340	Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. <i>Kidney International</i> , 2005, 68, 2639-2650.	2.6	96
341	Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. <i>Kidney International</i> , 2005, 68, 2714-2725.	2.6	110
342	Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. <i>Laboratory Investigation</i> , 2005, 85, 1292-1307.	1.7	213

#	ARTICLE	IF	CITATIONS
343	Mechanisms of immune-deposit formation and the mediation of immune renal injury. <i>Clinical and Experimental Nephrology</i> , 2005, 9, 183-191.	0.7	138
344	Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F1123-F1133.	1.3	90
345	Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3631-3641.	3.0	177
346	In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2661-2669.	0.4	70
347	Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. <i>FASEB Journal</i> , 2005, 19, 2023-2025.	0.2	104
348	Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System. <i>Current Hypertension Reviews</i> , 2005, 1, 67-76.	0.5	7
349	Protection of Endothelial Cells by Dextran Sulfate in Rats with Thrombotic Microangiopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2997-3005.	3.0	14
350	Cellular Response to Injury in Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1195-1204.	3.0	171
351	Blockade of Calcium Influx through L-Type Calcium Channels Attenuates Mitochondrial Injury and Apoptosis in Hypoxic Renal Tubular Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2320-2333.	3.0	73
352	Evidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1277-1288.	3.0	213
353	Accelerated Glomerular Injury in Hemi-Nephrectomized Transgenic Mice of Mesangial Cell-Predominant Serpin, Megsin. <i>Nephron Experimental Nephrology</i> , 2004, 96, e127-e133.	2.4	4
354	Hypoxia and Tubulointerstitial Injury: A Final Common Pathway to End-Stage Renal Failure. <i>Nephron Experimental Nephrology</i> , 2004, 98, e8-e12.	2.4	91
355	Critical Protection from Renal Ischemia Reperfusion Injury by CD55 and CD59. <i>Journal of Immunology</i> , 2004, 172, 3869-3875.	0.4	161
356	Hypoperfusion of Peritubular Capillaries Induces Chronic Hypoxia before Progression of Tubulointerstitial Injury in a Progressive Model of Rat Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1574-1581.	3.0	147
357	Transdifferentiation of cultured tubular cells induced by hypoxia. <i>Kidney International</i> , 2004, 65, 871-880.	2.6	172
358	Hypoxia in Renal Disease with Proteinuria and/or Glomerular Hypertension. <i>American Journal of Pathology</i> , 2004, 165, 1979-1992.	1.9	107
359	Mechanisms of Tubulointerstitial Injury in the Kidney: Final Common Pathways to End-stage Renal Failure. <i>Internal Medicine</i> , 2004, 43, 9-17.	0.3	294
360	Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 833-839.	2.1	129

#	ARTICLE	IF	CITATIONS
361	Hypoxia-induced apoptosis in cultured glomerular endothelial cells: Involvement of mitochondrial pathways. <i>Kidney International</i> , 2003, 64, 2020-2032.	2.6	61
362	Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1212-1222.	3.0	165
363	Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of Bax. <i>Biochemical and Biophysical Research Communications</i> , 2003, 309, 222-231.	1.0	65
364	Complement Regulatory Proteins: Are They Important in Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2411-2413.	3.0	7
365	Induction of Renoprotective Gene Expression by Cobalt Ameliorates Ischemic Injury of the Kidney in Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1825-1832.	3.0	239
366	Imbalance of T-Cell Subsets in Angiotensin II-Infused Hypertensive Rats With Kidney Injury. <i>Hypertension</i> , 2003, 42, 31-38.	1.3	190
367	In Vivo klotho Gene Transfer Ameliorates Angiotensin II-Induced Renal Damage. <i>Hypertension</i> , 2002, 39, 838-843.	1.3	237
368	Transcriptional Regulation of a Mesangium-Predominant Gene, Megsin. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2715-2722.	3.0	11
369	Contribution of genetically engineered animals to the analyses of complement in the pathogenesis of nephritis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 34-36.	0.4	10
370	Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2478-2487.	3.0	290
371	Glucose Dialysate Induces Mitochondrial DNA Damage in Peritoneal Mesothelial Cells. <i>Peritoneal Dialysis International</i> , 2002, 22, 11-21.	1.1	46
372	Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. <i>Kidney International</i> , 2002, 62, 679-687.	2.6	34
373	ETB receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. <i>Kidney International</i> , 2002, 62, 922-928.	2.6	17
374	Overexpression of the serpin meginin induces progressive mesangial cell proliferation and expansion. <i>Journal of Clinical Investigation</i> , 2002, 109, 585-593.	3.9	38
375	C6 Mediates Chronic Progression of Tubulointerstitial Damage in Rats with Remnant Kidneys. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 928-936.	3.0	114
376	Overexpression of the serpin meginin induces progressive mesangial cell proliferation and expansion. <i>Journal of Clinical Investigation</i> , 2002, 109, 585-593.	3.9	32
377	Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. <i>Kidney International</i> , 2001, 60, 2351-2359.	2.6	91
378	Cloning of rodent meginin revealed its up-regulation in mesangioproliferative nephritis. <i>Kidney International</i> , 2001, 60, 641-652.	2.6	21

#	ARTICLE	IF	CITATIONS
379	Increased Susceptibility of Decay-Accelerating Factor Deficient Mice to Anti-Glomerular Basement Membrane Glomerulonephritis. <i>Journal of Immunology</i> , 2001, 167, 2791-2797.	0.4	79
380	Protective Role of Nitric Oxide in a Model of Thrombotic Microangiopathy in Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2088-2097.	3.0	44
381	Cloning and Characterization of a Novel Subunit of Protein Serine/Threonine Phosphatase 4 from Mesangial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2601-2608.	3.0	21
382	C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, F747-F757.	1.3	81
383	Crry, a complement regulatory protein, modulates renal interstitial disease induced by proteinuria ¹¹ See Editorial by Quigg, p. 2315. <i>Kidney International</i> , 1999, 56, 2096-2106.	2.6	51
384	Complement Membrane Attack Complex (C5b-9) Mediates Interstitial Disease in Experimental Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2323-2331.	3.0	166
385	Expression of Megsin mRNA, a Novel Mesangium-Predominant Gene, in the Renal Tissues of Various Glomerular Diseases. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2606-2613.	3.0	39
386	Complement regulatory proteins in glomerular diseases. <i>Kidney International</i> , 1998, 54, 1419-1428.	2.6	110
387	The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. <i>Kidney International</i> , 1998, 54, 1934-1944.	2.6	54
388	Functional quantitative analysis of the genome in cultured human mesangial cells: Technical Note. <i>Kidney International</i> , 1998, 53, 154-158.	2.6	24
389	Renal catabolism of advanced glycation end products: The fate of pentosidine. <i>Kidney International</i> , 1998, 53, 416-422.	2.6	194
390	Increased Pentosidine, an Advanced Glycation End Product, in Plasma and Synovial Fluid from Patients with Rheumatoid Arthritis and Its Relation with Inflammatory Markers. <i>Biochemical and Biophysical Research Communications</i> , 1998, 244, 45-49.	1.0	145
391	A new model of renal microvascular injury. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 457-462.	1.0	15
392	Molecular mechanisms of experimental glomerulonephritis: an overview. <i>Nephrology</i> , 1997, 3, s633-s637.	0.7	7
393	Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. <i>Kidney International</i> , 1997, 51, 1088-1099.	2.6	94
394	A new model of renal microvascular endothelial injury. <i>Kidney International</i> , 1997, 52, 182-194.	2.6	70
395	Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo. <i>Kidney International</i> , 1997, 52, 404-413.	2.6	116
396	Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9. <i>Kidney International</i> , 1997, 52, 1570-1578.	2.6	39

#	ARTICLE	IF	CITATIONS
397	Transfected CD59 protects mesangial cells from injury induced by antibody and complement. <i>Kidney International</i> , 1996, 50, 257-266.	2.6	26
398	Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. <i>Kidney International</i> , 1996, 50, 1230-1239.	2.6	96
399	Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. <i>Kidney International</i> , 1996, 50, 2054-2062.	2.6	27
400	KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. <i>Cell</i> , 1994, 79, 1209-1220.	13.5	546
401	Hypophosphatasia in an adult: A case report.. <i>Japanese Journal of Medicine</i> , 1991, 30, 47-52.	0.1	7
402	Mitochondrial Damage Causes Inflammation Via cGAS-STING Signaling in Acute Kidney Injury. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3